Joined
·
590 Posts
A patient's acute lymphoblastc leukemia (ALL) has finally been beaten into remission, and you begin maintenance therapy with weekly doses of methotrexate. Methotrexate is a reversible, competitive inhibitor of dihydrofolate reductase, so it will:
- Decrease the Km of the enzyme but not affect the Vmax
- Decrease the Vmax of the enzyme but not affect the Km
- Increase the Km of the enzyme but not affect the Vmax
- Increase the Vmax and the Km of the enzyme
- Increase the Vmax of the enzyme but not affect the Km